Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

View all →   RSSRecent Releases
Jul 18, 2014 Celldex to Report Second Quarter 2014 Financial Results and Host Corporate 2014 Objectives Update Call
Jun 2, 2014 Celldex Therapeutics' Varlilumab Continues to Demonstrate Very Favorable Profile
What's New

2012 Form 10-K

More →Featured Events
May 14, 2014
4:20 PM PT
Bank of America Merrill Lynch 2014 Healthcare Conference
Nov 25, 2013
8:30 AM ET
Rindopepimut Phase 2 ReACT Program Update
Nov 7, 2013
8:30 AM ET
CDX-1127 Program Update
May 23, 2012
4:30 PM ET
Celldex Therapeutics, Inc. to Discuss Topline Results of Phase 2b EMERGE Study of CDX-011 Conference Call
Jan 23, 2012 Celldex Therapeutics, Inc. Research and Development Day
More →Upcoming Events
Aug 6, 2014
4:30 PM ET
Celldex Therapeutics Second Quarter Financial Results
Featured Financial Reports
Filing Date Title Type Size
May 1, 2014 Form 10-Q View HTML View PDF 297.7 KB Add to Briefcase
Mar 3, 2014 Form 10-K View HTML View PDF 909.7 KB Add to Briefcase
Add to Briefcase = add file to Briefcase